Business Context and Reporting Period
This Form 8-K Current Report was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on August 20, 2019. The filing discloses the entry into a Material Definitive Agreement for a registered direct offering and a concurrent private placement of equity securities.
Key Financial Metrics and Transaction Details
- Aggregate Gross Proceeds: Approximately $1.5 million (before estimated offering expenses).
- Securities Issued:
- 271,744 shares of Common Stock.
- Series E Pre-Funded Warrants to purchase up to 456,058 shares (exercisable immediately).
- Series F Warrants to purchase up to 707,802 shares (exercisable after six months).
- Pricing: Combined purchase price of $2.061 per Share/Series F Warrant. Series F Warrants have an exercise price of $1.936 per share.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels. This is a transactional filing, not a financial results report.
Material Changes and Restrictions
The primary material change is the capital raise of approximately $1.5 million. As part of the Purchase Agreement, the Company agreed to a 60-day lock-up period following the closing, during which it will not issue or agree to issue any shares of Common Stock or Common Stock equivalents, subject to certain exceptions.
Outlook, Risks, and Unusual Items
- Closing Conditions: The transaction is subject to the satisfaction of specified customary closing conditions.
- Registration Status: The Common Stock and Series E Pre-Funded Warrants are offered under an effective shelf registration statement (Form S-3). The Series F Warrants are unregistered, offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions.
- Warrant Terms: Series E Pre-Funded Warrants require a nominal exercise price of $0.01, with the remainder pre-funded. Both warrant series allow for cashless exercise under certain circumstances.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received after deducting offering expenses.
- Confirm the exact number of shares outstanding post-transaction to assess dilution impact.
- Review the definitive transaction documents (Exhibits 10.1, 10.2, and 10.3) for specific terms regarding warrant adjustments and cashless exercise provisions.
- Monitor compliance with the 60-day restriction on future stock issuances.